Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L, Triche TJ Jr, Farrar JE, Wai D, Legendre C, Gooden GC, Liang WS, Carpten J, Lee D, Alvaro F, Macy ME, Arndt C, Barnette P, Cooper T, Martin L, Narendran A, Pollard J, Meshinchi S, Boklan J, Arceci RJ, Salhia B. Gore L, et al. Among authors: narendran a. Clin Epigenetics. 2017 Oct 5;9:108. doi: 10.1186/s13148-017-0411-x. eCollection 2017. Clin Epigenetics. 2017. PMID: 29034009 Free PMC article. Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Bagatell R, et al. Among authors: narendran a. Clin Cancer Res. 2007 Mar 15;13(6):1783-8. doi: 10.1158/1078-0432.CCR-06-1892. Clin Cancer Res. 2007. PMID: 17363533 Clinical Trial.
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference. Horton TM, et al. Among authors: narendran a. Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414. Pediatr Blood Cancer. 2010. PMID: 20127846 Free PMC article.
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.
Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Hoeksema KA, et al. Among authors: narendran a. Onco Targets Ther. 2011;4:149-68. doi: 10.2147/OTT.S21553. Epub 2011 Sep 5. Onco Targets Ther. 2011. PMID: 21949608 Free PMC article.
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ. Abd Elmoneim A, et al. Among authors: narendran a. Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8. doi: 10.1002/pbc.24264. Epub 2012 Aug 8. Pediatr Blood Cancer. 2012. PMID: 22887831 Clinical Trial.
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors.
Gore L, Trippett TM, Katzenstein HM, Boklan J, Narendran A, Smith A, Macy ME, Rolla K; Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC); Narashimhan N, Squillace RM, Turner CD, Haluska FG, Nieder M. Gore L, et al. Among authors: narendran a. Clin Cancer Res. 2013 Jul 1;19(13):3649-58. doi: 10.1158/1078-0432.CCR-12-3166. Epub 2013 May 9. Clin Cancer Res. 2013. PMID: 23659969 Clinical Trial.
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM, Sison EAR, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown PA. Cooper TM, et al. Among authors: narendran a. Pediatr Blood Cancer. 2017 Aug;64(8):10.1002/pbc.26414. doi: 10.1002/pbc.26414. Epub 2017 Apr 14. Pediatr Blood Cancer. 2017. PMID: 28409853 Free PMC article. Clinical Trial.
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Macy ME, Kieran MW, Chi SN, Cohen KJ, MacDonald TJ, Smith AA, Etzl MM, Kuei MC, Donson AM, Gore L, DiRenzo J, Trippett TM, Ostrovnaya I, Narendran A, Foreman NK, Dunkel IJ. Macy ME, et al. Among authors: narendran a. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26621. doi: 10.1002/pbc.26621. Epub 2017 May 24. Pediatr Blood Cancer. 2017. PMID: 28544128 Free PMC article.
130 results